Home » Psychedelics and the healthcare system: assisted therapy makes its way in Spain

Psychedelics and the healthcare system: assisted therapy makes its way in Spain

psychedelics and the healthcare system

For decades, psychedelics occupied a marginal place in the Western medical imagination: substances associated with excess, disorder or counterculture, closer to myth than to clinical protocol. Yet many hospitals, universities and private practices have been taking an interest in these substances for years. Not abruptly or triumphantly, but through clinical trials, ethical debates and pilot experiences that directly challenge the contemporary health system.

The question no longer revolves around whether psychedelics “work”, but how, under what conditions and within what frameworks they could be integrated — if that proves possible — into clinical practice.

From prohibition to the laboratory

The so-called “psychedelic renaissance” did not come out of nowhere. Since the start of this millennium, institutions such as Johns Hopkins University, Imperial College London or MAPS have driven rigorous studies on the therapeutic use of substances such as psilocybin, MDMA or ketamine in treating resistant depression, post-traumatic stress disorder or anxiety associated with serious illness.

The results, published in prestigious journals such as The New England Journal of Medicine or Nature Medicine, showed significant clinical improvements in controlled settings. The psychiatrist and neuroscientist Robin Carhart-Harris puts it precisely: “We are not talking about drugs that silence symptoms, but about experiences that reconfigure the patient’s relationship with their suffering”.

Spain was not left out of this trend, although its progress was more discreet. Research teams linked to universities, hospitals and private centres began to explore, cautiously, the clinical possibilities of these compounds, always under the umbrella of authorised trials and strict protocols.

Ketamine: the door ajar

In the Spanish context, ketamine holds a singular place. Unlike other classic psychedelic substances, its prior medical use as an anaesthetic allowed an earlier incorporation in the treatment of resistant depression, especially as an intravenous infusion or intranasal esketamine.

Some private clinics already offer ketamine treatments integrated into psychotherapeutic processes, while certain hospitals are evaluating its use in specialised units. Even so, professionals insist on the need for caution. “In the next five years,” warns Dr Albert Garcia Romeu, “it could become possible for a clinic offering psychedelic-assisted therapy to help people with substance use, depression, PTSD and other conditions in the same setting”.

Context, preparation and support can make the difference between a therapeutic intervention and a destabilising experience. This points to one of the central knots of the debate: the care model.

Psychedelics and the health system

Beyond the drug: experience, context and bond

Unlike conventional psychiatric drugs, psychedelic-assisted therapies cannot be reduced to a prescription. They require time, continuous professional presence and a solid ethical framework. Psychological preparation beforehand, accompanied sessions, integration spaces afterwards and interdisciplinary trained teams.

The psychiatrist Stanislav Grof, a pioneer in this field, warned decades ago that “the therapeutic effect does not reside in the molecule, but in the experience lived under the right conditions”. This perspective clashes head-on with health systems designed for brief, standardised, highly protocolised interventions.

The question is uncomfortable but unavoidable: can the health system accommodate practices that demand slowness, listening and symbolic complexity?

Legal, ethical and cultural barriers

On top of the structural difficulties come regulatory obstacles. In Spain, most psychedelics remain classified as prohibited substances, even when scientific evidence supports their therapeutic potential in controlled settings. This limits both research and professional training and creates a vacuum that sometimes leads to unregulated offers outside the health sphere.

From an ethical perspective, many specialists warn about the risk of lightly moving these practices into the private market without clear patient-protection frameworks. As Nora Volkow, director of the National Institute on Drug Abuse, has warned, even when psychedelics show rapid effects, “the expectation of an immediate response must not eclipse the complexity of human suffering or the need for continued clinical support”, a caution that is especially relevant when intense experiences are incorporated into therapeutic frameworks still under construction.

In the words of Rick Doblin, founder of MAPS, “psychedelics do not do the work for the person; they create a window of opportunity that can facilitate the therapeutic process, but without adequate support it can also amplify vulnerability”.

Between the clinical and the ritual

The debate is not limited to the medical sphere. Alongside clinical interest, ritual, spiritual or traditional contexts persist for practices with substances such as ayahuasca or psilocybin mushrooms. Although the two worlds — the health world and the ceremonial one — answer to different logics, their coexistence raises relevant questions.

Some professionals call for an honest dialogue that makes it possible to distinguish, without ranking or confusing, between cultural practices, personal experiences and clinical therapies. Others stress the importance of not indiscriminately medicalising traditional knowledge nor, conversely, legitimising clinical practices lacking ethical and scientific backing.

Where to look next?

More than an immediate revolution, the horizon taking shape points to a gradual, critical and responsible integration. Specialised training for health professionals, legal frameworks adapted to the evidence, independent public research and a mature social conversation about risks and limits.

As the psychiatrist Viktor Frankl recalled, “when we are no longer able to change a situation, we are challenged to change ourselves”. Perhaps the challenge psychedelics pose to the health system is not only to add new therapeutic tools, but to rethink what we mean by care, mental health and human support.

The debate remains open. And, far from being settled by uncritical enthusiasm or automatic rejection, it demands information, rigour and an ethics of care equal to the experience it proposes.

Keep reading

Funded by the European Union - NextGenerationEURecovery, Transformation and Resilience Plan (Spain)

Funded by the European Union – NextGenerationEU